AboutLifeTree
About Lifetree - Who We Are Our Philosophy Executive Management Team: Alice A. Jackson, R.N. Lynn R. Webster, MD, FACPM, FASAM Matthew Iverson Sean Kotrady, CCRC, CCRP Neuroscience Research Team: Miroslav "Misha" Bačkonja, MD Mark A. Johnston, MD N. Lee Smith, MD Daniel B. Vine, MD Mary Jane Norman, MD Dennis Thoen, MD Debra F. Hobbins, DNP, APRN, LSAC, CARN-AP
ClinicalResearch
THERAPEUTIC EXPERTISE Clinical Research Abstracts Abuse Liability Analgesia Pain Model Development Lifetree Center for Neuroscience Research Phase 1 Research Sleep Medicine Ophthalmology
Clinical TrialManagement
Clinical Trial Management Data Management Services Interactive Voice Response System Medical and Safety Management Medical Writing Biostatistics and Analysis Services Drug Development Services
PressRoom
Press Releases & News Media Coverage Research Articles Calendar of Events
ContactLifeTree
Contact Lifetree Employment Opportunities For Study Participants For Biopharmaceutical and Device Clients Physicians: Become a Lifetree Investigator
VolunteerFor a Study
Volunteer - Screening Survey Current Research Studies Clinical Research Studies: Alzheimer's Clinical Trial Bunion Removal Chlamydia Home Testing Kit Chronic Pain Chronic Pain from Post-Herpetic Neuralgia Depression Clinical Trial Diabetic Peripheral Neuropathy Drug Abuse Study - Recreational use of Prescription Medications Gonorrhea Home Testing Kit Healthy Males and Females Healthy Seniors Hepatitis C Clinical Trial High Blood Pressure Hypertension Low Back Pain Mild Dementia Migraine Headaches Multiple Sclerosis Opioid Induced Constipation Osteoarthritis of the Hip and or Knee Schizophrenia Clinical Trial Sciatica Suboxone Wisdom Teeth Removal

Articles

< back to Articles

Date: Aug 30 2011

Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users

Introduction

Opioid analgesics are an important component of comprehensive management plans for chronic pain in appropriately selected and monitored patients. Extended-release opioid formulations have enabled patients to attain around-the-clock pain relief with less frequent dosing than with immediate-release products; however, they are vulnerable to tampering by abusers wishing to gain access to the larger supply of opioid within each dose unit.[1,2]

Read the full article